Substance / Medication

Omeprazole

Overview

Active Ingredient
omeprazole
RxNorm CUI
7646
Labeler: PD-Rx Pharmaceuticals, Inc.Updated: 2026-02-25T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

5.2 (6) • Omeprazole delayed-release capsules are contraindicated in patients with known hypersensitivity reactions including anaphylaxis to the formulation or any substituted benzimidazole. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubul

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

54 trials linked to this intervention

54
Total Trials
7
Recruiting
23
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Esomeprazole covalently interacts with the cardiovascular enzyme dimethylarginine dimethylaminohydrolase: Insights into the cardiovascular risk of proton pump inhibitors.
Smith Clyde A, Ebrahimpour Afshin, Novikova Lyudmila et al. · Biochim Biophys Acta Gen Subj · 2022
PMID: 35472493Meta-AnalysisFull text (PMC)
Is the use of esomeprazole in gastroesophageal reflux disease a cost-effective option in Poland?
Petryszyn Pawel, Staniak Aleksandra, Grzegrzolka Jedrzej · J Comp Eff Res · 2016
PMID: 26946951Meta-Analysis
Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection.
McNicholl A G, Linares P M, Nyssen O P et al. · Aliment Pharmacol Ther · 2012
PMID: 22803691Meta-Analysis
[Omeprazole of limited value in crying babies].
Blokpoel Robert G T, Broos Nancy, de Jong-van den Berg Lolkje T W et al. · Ned Tijdschr Geneeskd · 2010
PMID: 20719016Meta-Analysis
Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs.
Hawkey C J, Jones R H, Yeomans N D et al. · Aliment Pharmacol Ther · 2007
PMID: 17373920Meta-Analysis
Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials.
Gralnek Ian M, Dulai Gareth S, Fennerty M Brian et al. · Clin Gastroenterol Hepatol · 2006
PMID: 17162239Meta-Analysis
A meta-analysis: comparison of esomeprazole and other proton pump inhibitors in eradicating Helicobacter pylori.
Wang Xia, Fang Jing-Yuan, Lu Rong et al. · Digestion · 2006
PMID: 16837803Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Omeprazole (substance)
SNOMED CT
387137007
UMLS CUI
C0028978
RxNorm CUI
7646
Labeler
PD-Rx Pharmaceuticals, Inc.

Clinical Data

This intervention maps to 5 entities in the Ltrl knowledge graph.

5
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
54
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.